12:00 AM
 | 
May 20, 2013
 |  BC Week In Review  |  Company News  |  Other News

Spectrum Pharmaceuticals cancer news

Spectrum disclosed in an SEC filing that it received a subpoena in April from the SEC to produce documents related to the company's 2012 earnings announcement that it expected a "change in ordering patterns" of cancer drug Fusilev levoleucovorin. In March, the company lowered its...

Read the full 213 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >